Pharmicell announced on May 9 that its research project titled "Development of a Therapeutic Agent for Obstructive Nephropathy Using Multifunctional Mesenchymal Stem Cells Based on Melatonin and Valproic Acid Mixed Priming" has been selected for the 2025 Pan-Ministerial Regenerative Medicine Technology Development Project.
The Pan-Ministerial Regenerative Medicine Technology Development Project is an initiative led by the Ministry of Science and ICT and the Ministry of Health and Welfare, aimed at securing core source technologies for regenerative medicine and obtaining regenerative medical therapeutics and treatment technologies through clinical integration. For the selected project, Asan Medical Center will serve as the lead institution, with Pharmicell and Ewha Womans University Mokdong Hospital participating as joint research institutions.
Obstructive nephropathy is a disease in which urinary flow is delayed due to urinary tract obstruction, resulting in kidney damage, kidney stones, and infections, causing significant inconvenience in daily life. Existing treatments focus on alleviating the cause of the obstruction, but they lack completeness, and if the cause is not resolved quickly, it can lead to permanent loss of kidney function and a decline in quality of life.
There is a strong need for new therapeutics that can supplement simple behavioral therapy and existing drugs. The technology being developed through this project aims to present a new treatment alternative for patients with obstructive nephropathy by developing "MVP-MSC," which enhances the antioxidant capacity and therapeutic efficacy of stem cells without genetic modification.
A Pharmicell representative stated, "Through this research, we aim to dramatically improve treatment outcomes for patients with obstructive nephropathy, which will also contribute significantly to reducing medical expenses and decreasing the prevalence of complications related to loss of kidney function."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
